Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIDeNT / TRIBECA: Nivolumab plus Targeted Therapy in BRAF-mutated Metastatic Melanoma
NCT02910700Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2016
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab in melanoma (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Objective Response Rate up to 3 years. Started Dec 2016; status: active, not recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02910700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02910700.